Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Lupin Adds Technical And IT Chiefs

Meanwhile, Mallinckrodt Promotes Branded Chief And Australia’s GBMA Shuffles Board

Executive Summary

Lupin has appointed a pair of executives to handle technical operations and information technology. At the same time, Mallinckrodt has promoted its head of brands to the firm’s executive committee and Australia’s GBMA association has made major changes to its board.

You may also be interested in...



Australia steps up its bio education efforts

An information campaign on biosimilars being conducted by Australia’s Generic and Biosimilar Medicines Association (GBMA) has been launched under the leadership of Renée Richardson, who has just been appointed project manager of the association’s educational arm GBMA Education. GBMA chair Sylvain Vigneault said Richardson was a “highly accomplished project manager with extensive experience in healthcare program development”.

Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.

Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision to cut sales staff for its Cyltezo US biosimilar rival to Humira not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the struggles for Humira biosimilars more widely.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel